Mounjaro 7.5 mg is used in endocrinology for the following indications: 🔹 Type 2 Diabetes Mellitus: As monotherapy (in cases of metformin intolerance) or as part of combination treatment to achieve target glycated hemoglobin levels. 🔹 Obesity and Overweight Management: For long-term weight management in adults with a BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) in the presence of weight-related comorbidities.

Dosage and administration

Sales Form: 1 multi-dose KwikPen (2.4 ml of solution) containing 4 doses of 7.5 mg.⚠️ INSTRUCTIONS FOR USE: Dosage Regimen: The drug is administered once a week on the same day. The 7.5 mg dose is usually prescribed after completing a four-week course of the 5 mg dosage. Method of Administration: Subcutaneous injection into the abdomen, thigh, or upper arm. Rotate the injection site each time. Schedule Flexibility: If you miss a dose, it can be administered within 4 days after the missed date. Storage: Before first use, store the pen in the refrigerator at 2°C–8°C. After starting use, the pen can be stored at room temperature (up to 30°C) for no more than 21 days. Keep from freezing!

⛔ Oncological Awareness: Personal or family history of medullary thyroid carcinoma. ⛔ Genetic Disorders: Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). ⛔ Allergic Reactions: Individual hypersensitivity to tirzepatide or any component of the drug. ⛔ Pregnancy and Lactation: Mounjaro is contraindicated for pregnant and breastfeeding women. ⛔ Special Conditions: Severe gastrointestinal diseases (including gastroparesis), history of pancreatitis, severe renal impairment.

The transition to the 7.5 mg dosage may be accompanied by temporary bodily reactions: 🤢 Gastrointestinal Tract: Nausea, diarrhea, decreased appetite, vomiting, constipation, and heartburn are most common. These symptoms usually subside within 1-2 weeks. ⚡ Energy Levels: Possible increased fatigue or mild dizziness. 🩹 Local Reactions: Redness or itching at the injection site. ⚠️ Important Warnings: If severe abdominal pain (a sign of potential pancreatitis) or severe vomiting occurs, consult a doctor immediately. It is recommended to drink plenty of water to prevent dehydration.

Mounjaro KwikPen 7.5 — Tirzepatide 7.5 mg, 1 pcs, Eli Lilly India

100% original product

Active ingredient

Tirzepatide

Manufacturer

Eli Lilly India

Dosage 7.5 mg

Dosage form Prefilled pen

Pens per pack 1

Mounjaro KwikPen 7.5 — Tirzepatide 7.5 mg (1 Pen / 4 Doses)

Name: Mounjaro KwikPen 7.5
Brand: Eli Lilly India
SKU: PROD-269
Price: 21093 UAH
Availability: InStock

21093₴ ~~22064₴~~ -4%

Mounjaro KwikPen 7.5 mg (Tirzepatide) is an innovative, next-generation injectable medication designed for the treatment of type 2 diabetes and effective weight loss. Tirzepatide is the first-in-class dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The synergy of these two hormones provides a powerful impact on metabolism, allowing for significant results in glucose control and body weight correction.

Manufacturer: Eli Lilly. The KwikPen format is a multi-dose pre-filled pen that makes the injection process as simple and precise as possible. The 7.5 mg dosage is an important titration step designed to enhance the therapeutic effect after the body has adapted to the initial doses (2.5 mg and 5 mg).

✅ Dual Mechanism of Action: Unlike single-hormone drugs, Mounjaro activates two types of receptors simultaneously, leading to more pronounced weight loss and an improved glycemic profile.
✅ Ease of Use: The KwikPen contains 4 doses of 7.5 mg each, providing a full one-month course of treatment.
✅ Comprehensive Health Benefits: In addition to sugar control, the drug contributes to lower blood pressure, improved blood lipid levels, and a reduction in visceral fat.

Mounjaro 7.5 mg is used in endocrinology for the following indications:

🔹 Type 2 Diabetes Mellitus: As monotherapy (in cases of metformin intolerance) or as part of combination treatment to achieve target glycated hemoglobin levels.
🔹 Obesity and Overweight Management: For long-term weight management in adults with a BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) in the presence of weight-related comorbidities.

Sales Form: 1 multi-dose KwikPen (2.4 ml of solution) containing 4 doses of 7.5 mg.

⚠️ INSTRUCTIONS FOR USE:

Dosage Regimen: The drug is administered once a week on the same day. The 7.5 mg dose is usually prescribed after completing a four-week course of the 5 mg dosage.
Method of Administration: Subcutaneous injection into the abdomen, thigh, or upper arm. Rotate the injection site each time.
Schedule Flexibility: If you miss a dose, it can be administered within 4 days after the missed date.
Storage: Before first use, store the pen in the refrigerator at 2°C–8°C. After starting use, the pen can be stored at room temperature (up to 30°C) for no more than 21 days. Keep from freezing!

⛔ Oncological Awareness: Personal or family history of medullary thyroid carcinoma.
⛔ Genetic Disorders: Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
⛔ Allergic Reactions: Individual hypersensitivity to tirzepatide or any component of the drug.
⛔ Pregnancy and Lactation: Mounjaro is contraindicated for pregnant and breastfeeding women.
⛔ Special Conditions: Severe gastrointestinal diseases (including gastroparesis), history of pancreatitis, severe renal impairment.

The transition to the 7.5 mg dosage may be accompanied by temporary bodily reactions:

🤢 Gastrointestinal Tract: Nausea, diarrhea, decreased appetite, vomiting, constipation, and heartburn are most common. These symptoms usually subside within 1-2 weeks.
⚡ Energy Levels: Possible increased fatigue or mild dizziness.
🩹 Local Reactions: Redness or itching at the injection site.
⚠️ Important Warnings: If severe abdominal pain (a sign of potential pancreatitis) or severe vomiting occurs, consult a doctor immediately. It is recommended to drink plenty of water to prevent dehydration.